Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

2679 - Baseline Quality of life (QoL) and chemotherapy related toxicities (CRT) in localized breast cancer (BC) patients (pts): the French multicentric prospective CANTO cohort study


29 Sep 2019


Poster Display session 2


Tumour Site

Breast Cancer


Idlir Licaj


Annals of Oncology (2019) 30 (suppl_5): v55-v98. 10.1093/annonc/mdz240


I. Licaj1, S. Dabakuyo2, S. Dauchy3, I. Vaz Luis4, C. Charles5, C. Lemogne6, O. Tredan7, L. Vanlemmens8, C. Jouannaud9, C. Levy10, O. Rigal11, M. Fournier12, T. Petit13, F. Dalenc14, P. Rouanet15, A. Arnaud16, J. Lemonnier17, S. Everhard17, P.H. Cottu18, F. Joly19

Author affiliations

  • 1 Clinical Research, Centre Francois Baclesse, 14076 - Caen/FR
  • 2 Biostatistics And Quality Of Life Unit, Centre Georges François Leclerc, 21000 - Dijon/FR
  • 3 Department Of Supportive Care, Gustave Roussy, Villejuif/FR
  • 4 Departement Of Medical Oncology, Gustave Roussy, Villejuif/FR
  • 5 Psycho-oncology Unit, Gustave Roussy, 94800 - Villejuif/FR
  • 6 Hopital Européen Georges-pompidou, APHP, 75015 - Paris/FR
  • 7 Department Of Oncology, Centre Leon Berard, 69007 - Lyon/FR
  • 8 Département De Cancérologie Sénologique, Centre Oscar Lambert, Lille/FR
  • 9 Department Of Medical Oncology, Institut Jean Godinot, 51100 - Reims/FR
  • 10 Department Of Medical Oncology, Centre Francois Baclesse, 14076 - Caen/FR
  • 11 Medical Oncology, Centre Henri-Becquerel, 76000 - Rouen/FR
  • 12 Surgery, Institut Bergonié, 33000 - Bordeaux/FR
  • 13 Medical Oncology, Centre Paul Strauss, 67000 - Strasbourg/FR
  • 14 Medical Oncology, Centre Claudius-Regaud, 31052 - Toulouse/FR
  • 15 Surgical Oncology, ICM, 34000 - Montpellier/FR
  • 16 Medical Oncology, Clinique Ste Catherine, Avignon/FR
  • 17 Clinical Research, Unicancer, 75000 - Paris/FR
  • 18 Medical Oncology, Institut Curie, 75005 - Paris/FR
  • 19 Medical Oncology, Centre Francois Baclesse, 14000 - CAEN/FR


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 2679


In this study we aimed to examine the independent effect of baseline QoL and persistent CRT among pts with early BC.


We included data stage I-III BC pts treated with chemotherapy who were included in the CANTO prospective cohort study (NCT-01993498) from 03/2012 to 12/2014. The primary outcome was CRT defined as the presence at 3-6 months after the end of treatment, of any of the following toxicities (NCI-CTC-AE): infection, venous or arterial thrombosis, neurological G2-4, digestive G3-4 or pulmonary toxicities G3-4). Treatment deliver including chemotherapy dose reductions were also examined. The independent variable of this study was baseline Qol defined by the EORTC QLQ-C30 subscales of general global health status (GHS) (< or ≥ 70) and physical functioning PF (< or ≥ 90). The defined cutoffs correspond to the average values in the French general population. Clinical relevant adjustment covariates included stage, age, performance status (PS), body mass index (BMI), HR and HER2 status, baseline lymphopenia, albumin, creatinine clearance, alcohol consumption, and smoking status. Multivariable logistic models were performed.


Among 3079 BC pts included in this analysis, 33% received neoadjuvant and 77% adjuvant treatment. Median age at diagnosis was 53 years, median BMI= 25 kg/m2, 94% of patients had a PS = 0 and 83% stage I-II disease. Pts reported on average a good GHS = 68 (±19) and PF = 90 (±14). GHS and PF were higher in women with better performance status PS = 0 vs 1+, (68 vs 60 p < 0.001) and 91 vs 78 p < 0.001) respectively. 952 (31%) BC pts developed ≥1 CRT: 23% had an infection, 7% thrombosis, 0.3% G3-4 diarrhea, nausea or vomiting, 4% G2-4 neurological and 0.2% G3-4 pulmonary toxicities. 16% had chemotherapy dose reduction. Pts with a baseline GHS <70 had 19 % higher odds of CRT vs to those with GHS≥70, OR = 1.19 [95% CI 1.02-1.41] and similarly those with a PF < 90 had a 23% higher odds of CRT when compared to those with PF ≥ 90 (OR = 1.23 [95% CI 1.03-1.49]).


Global and physical QoL before BC treatments are independently associated with CRT. QoL should be assessed before any treatment to identify patients at risk CRT.

Clinical trial identification


Editorial acknowledgement

Legal entity responsible for the study

UNICANCER/Villejuif, France, 94805 Principal Investigator: Fabrice André Gustave Roussy – Villejuif.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.